Diabetes (type 2) - pioglitazone (replaced by TA63)
Summary
This guidance has been replaced by Diabetes (type 2) - glitazones (review).
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA21
Issued: March 2001
How this guidance was produced